A15. Prescribed List Assessment Processes: An Evaluation
Tracks
Reimbursement/Market Access
| Tuesday, June 3, 2025 |
| 2:45 PM - 3:45 PM |
| C2.4 |
Chair & Speakers
Mr Paul Dale
Director, Policy
Medical Technology Association of Australia
Prescribed List Assessment Processes: An Evaluation
Abstract
This is the first public analysis of Prescribed List (PL) decision making and success rates. Hundreds of decisions about listing PL items are made every listing cycle (3 times a year) and yet little is known about the results of these decisions and what the key drivers are of success or failure. This obscures the process and prevents improvement of the process and individual sponsor applications. The main impediments to successful listing will be examined and some potential solutions offered.
Biography
Paul Dale has 25 years of experience in the medical technology and biopharmaceutical industries spanning local and global roles across pricing, reimbursement, market access, consulting and commercialisation. For the past 6 years he has been Director of Policy at the Medical Technology Association of Australia (MTAA), responsible for policy development for the industry in device reimbursement and digital health. From 2019 to 2023, Paul was MTAA’s representative on the Prostheses List Advisory Committee providing advice to the Commonwealth Department of Health on listing of devices on the Prostheses List (now Prescribed List). Paul has a degree in Public Policy from the University of Sydney.
Omar Khan
MTAA
A15. Prescribed List Assessment Processes: An Evaluation
Biography
